Investigating immune factors affecting treatment outcomes in neuroblastoma among different racial groups
Tumor and Host Immune signatures associated with health disparities in outcomes following GD2 immunotherapy in neuroblastoma
This study is looking into why Black children with neuroblastoma don't do as well with a specific treatment compared to White children, focusing on how certain immune cells might affect the treatment's success, and it aims to find out more about the reasons behind these differences so that all kids can get better care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10980735 on NIH RePORTER |
What this research studies
This research focuses on understanding why Black children with neuroblastoma experience worse outcomes after receiving GD2 immunotherapy compared to their non-Hispanic White counterparts. It examines the role of immune cells, particularly natural killer (NK) cells, and how their presence or exhaustion in tumors may influence treatment effectiveness. By analyzing biological factors and social determinants of health, the study aims to uncover the underlying reasons for these disparities. Patients may be involved in trials assessing the effectiveness of immunotherapy in relation to their immune profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old diagnosed with high-risk neuroblastoma, particularly those of African descent.
Not a fit: Patients with neuroblastoma who are not of African descent or those who do not meet the age criteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for neuroblastoma that are tailored to address racial disparities in patient outcomes.
How similar studies have performed: Previous research has indicated that immune cell profiles can significantly impact treatment responses, suggesting that this approach may yield valuable insights.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Goldsmith, Kelly C — Emory University
- Study coordinator: Goldsmith, Kelly C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.